key: cord-0944668-6stkn7pk
authors: Angel-Korman, Avital; Peres, Esther; Bryk, Gabriel; Lustig, Yaniv; Indenbaum, Victoria; Amit, Sharon; Rappoport, Vladimir; Katzir, Zeev; Yagil, Yoram; Iaina, Nomy Levin; Leiba, Adi; Brosh-Nissimov, Tal
title: Diminished and waning immunity to COVID-19 vaccination among hemodialysis patients in Israel: the case for a third vaccine dose
date: 2021-10-12
journal: Clin Kidney J
DOI: 10.1093/ckj/sfab206
sha: babb4fdd0ad49d5596bb2f9295f425c489439650
doc_id: 944668
cord_uid: 6stkn7pk

BACKGROUND: Humoral responses to COVID-19 vaccines in hemodialysis patients can direct vaccination policy. METHODS: We compared 409 COVID-19 naïve hemodialysis patients from 13 hemodialysis units in Israel to 148 non-dialysis dependent COVID-19 naïve controls. Twenty-four previously infected (anti-nucleocapsid positive) hemodialysis patients were analyzed separately. Blood samples were obtained ≥ 14 days post vaccination (BNT162b2) to assess seroconversion-rates and titers of anti-S and neutralizing antibodies. RESULTS: Median time from vaccination to blood sample collection was 82 (IQR 64–87) and 89 (IQR 68–96) days, for hemodialysis patients and controls, respectively. Seroconversion rates were lower in hemodialysis patients compared to controls for both anti-S and neutralizing antibodies (89% and 77% vs. 99.3%, respectively, P < 0.0001). Antibody titers were also significantly lower in hemodialysis patients compared to controls: median 69.6 (IQR 33.2–120) vs. 196.5 (IQR 118.5–246), P < 0.0001; geometric mean titer 23.3 (95% CI 18.7–29.1) vs. 222.7 (95% CI 174–284), P < 0.0001, for anti-S and neutralizing antibodies, respectively. Multivariate analysis demonstrated dialysis dependence to be strongly associated with lower antibody responses and antibody titers waning with time. Age, low serum albumin and low lymphocyte count were also associated with lower seroconversion rates and antibody titers. Hemodialysis patients previously infected with SARS-COV-2 had no difference in their seroconversion rates or antibody titers compared to COVID-19 naïve patients. CONCLUSION: This study demonstrates diminished and waning humoral responses following COVID-19 vaccination in a large and diverse cohort of hemodialysis patients, including those previously infected with SARS-CoV-2. Considering these results and reduced vaccine effectiveness against variants of concern, in addition to continued social-distancing precautions, a third booster dose should be considered in this population.

Multivariate analysis demonstrated dialysis dependence to be strongly associated with lower antibody responses and antibody titers waning with time. Age, low serum albumin and low lymphocyte count were also associated with lower seroconversion rates and antibody titers.

The mRNA-based COVID-19 vaccine BNT162b2 by Pfizer/BioNTech received emergency authorization by the FDA in November 2020, following a phase III study which included more than 43,000 subjects. Over a follow up period of 3 months the vaccine showed 95% efficacy against symptomatic SARS CoV-2 1 .

Various studies have shown high real-world vaccine effectiveness in prevention of severe disease, hospitalization and death related to COVID-19 [1] [2] [3] [4] [5] . Nevertheless, diminished effectiveness was shown in patients with multiple comorbidities 6 . Moreover, patients with severe breakthrough SARS-CoV-2 infections leading to hospitalizations have been found to have a high rate of comorbidities and immunosuppression 7 . Diminished immunogenicity has been previously reported in immunocompromised patients, including patients with hematological malignancies, transplant recipients and patients receiving immunosuppressive therapy [8] [9] [10] [11] [12] [13] .

Patients with ESRD are known to have reduced immune responses 14 Venous blood was drawn from patients and controls at least 14 days following the second dose of BNT162b2 vaccination and assayed for SARS-CoV-2 anti-spike (anti-S),

anti-nucleocapsid (anti-N) and SARS-CoV-2 neutralizing antibody levels.

Humoral response assessment:

Anti-spike (anti-S) antibody levels were tested with the LIAISON ® SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Saluggia, Italy), which targets the S1 and S2 subunits of the Outcomes:

We analyzed four serological outcomes: the post-vaccination seropositivity rate with the anti-S and the neutralization assays, and the antibody titers achieved by vaccination in these two assays. 

The original study cohort included 436 MHD patients and 163 controls. One MHD patient withdrew consent prior to obtaining blood samples. Two more MHD patients were excluded as less than 14 days had passed from the date of second vaccine dose to blood sampling. Twenty-four MHD and 15 control samples were found to have anti-N positive tests, signifying previous SARS-CoV-2 infection, and were therefore analyzed separately.

The final analysis included a cohort of COVID-19 naïve subjects: 409 MHD patients and 148 controls, and the cohort of previously infected subjects composed of 24 MHD patients and 15 controls ( Figure 1 ).

The time from vaccination to sampling ranged from 15 to 120 days, but the medians were more than 80 days (IQR 65-90), satisfying the goal for a late (2-3 month) assessment of immunogenicity.

The subjects' demographic characteristics, seroconversion rates and antibody titers are presented in Table 1 Figure 2b ).

Importantly, anti-S and neutralizing antibodies in both control and study group participants were strongly correlated (Spearman correlation coefficient r s =0.84).

On multivariate analysis also including age and sex, dialysis dependence was strongly associated with reduced seroconversion rates and antibody titers ( Figure 3 and supplementary tables S1-S4). MHD patients had 54.2% and 76.5% reduced anti-S and neutralizing antibody titers, respectively, compared to controls, whereas age had a more modest contribution to titer decline, with 18% and 36.8% decreases per decade, respectively.

Clinical and laboratory characteristics including comorbidities, dialysis related details and etiologies for ESRD as well as humoral responses of COVID-19 naïve MHD patients are presented in Table 2 .

Of the 364 naïve MHD patients who had positive anti-S antibodies, 57 (15.7%) did not develop neutralizing antibodies. Anti-S seropositivity (seroconversion) in MHD patients was significantly associated with younger age, higher albumin level, higher absolute lymphocyte count, higher hemoglobin levels, and higher serum iron levels, and negatively associated with use of immunosuppressive medications including use of steroids, calcineurininhibitors (CNIs), rituximab and chemotherapy (all at the time of blood sampling). Other comorbidities, dialysis vintage, Kt/Vurea, etiology of ESRD, residual urine output, previous kidney transplantation, and the time from vaccination to blood sampling were not significantly associated with anti-S positivity ( Table 2) .

For neutralizing antibodies, seropositivity was significantly associated with younger age, higher albumin level, higher absolute lymphocyte count serum iron level and negatively associated with immunosuppressive therapy as well as the time from vaccination to blood sampling ( Table 2) .

On univariate analysis, higher anti-S and neutralizing antibody titers were associated with younger age, higher albumin levels and higher absolute lymphocyte count and

negatively associated with longer time from vaccination to blood sampling and immunosuppressive medications (Supplementary Table S5 ).

Multivariable logistic regression analysis, for variables influencing anti-S and neutralizing antibodies, verified that younger age remained significantly associated with neutralizing antibodies for seroconversion, and with titer levels of both antibody types.

Higher albumin level remained significantly associated with anti-S seropositivity, and with titer levels of both anti-S and neutralizing antibodies. Higher absolute lymphocyte count remained significantly associated with seropositivity and titer levels of neutralizing antibodies. Immunosuppression remained negatively associated with seroconversion and titer levels for both anti-S and neutralizing antibodies. Longer time from vaccination to blood sampling remained associated with seronegativity of neutralizing antibodies (Table 3) and

with titer levels for both antibody types. (Figure 4 , Supplementary Table S6) .

Considering that MHD patients are routinely vaccinated against Hepatitis B, we compared their anti-HBsAb seropositivity and titer levels to the SARS-CoV-2 antibodies seroonversion rates and titer levels following the second dose of BNT162b2 vaccine. Anti-S seroconversion rates were not significantly associated with anti-HBsAb titers (p=0.14), however the association was significant for neutralizing antibodies seropositivity (p=0.04).

(Table 2, Figure 4 ).

In a univariate analysis, anti-S and neutralizing antibody titers were only weakly associated with anti-HBsAb titers (Spearman correlation r s =0.18 and r s =0.16, p<0.01;

respectively; Table 2 ). Accordingly, multivariate analysis demonstrated a very weak effect of anti HBsAb titers on both anti-S and neutralizing antibodies titers: 1% per 100IU/ml ( Figure   4) .

Twenty (Table 4) .

Similar to the findings in previous studies this study confirms that when MHD patients are compared to healthy controls, older age and being on maintenance hemodialysis confers a higher risk for lack of seroconversion, as well as for lower antibody titers 21,22 .

Notably, the effect of being dialysis dependent was much more pronounced than advancing age, on both seroconversion and both antibody titer levels. 

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Reply

BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel

Reduced humoral response to mRNA SARS-Cov-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: Not alarming, but should be taken gravely

BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases

Antibody responses to SARS-CoV-2 infection are attenuated in infliximabtreated patients with IBD

Aspects of immune dysfunction in end-stage renal disease

Practical Guide to Vaccination in All Stages of CKD, Including Patients Treated by Dialysis or Kidney Transplantation

Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients

Albumin: median

ESRD, end stage renal disease

ADPKD, autosomal dominant polycystic renal disease; HBsAb, hepatitis B surface antibody

The authors wish to thank Mrs. Irena Perchikov, Mrs. Tatiana Sharipov and Mrs. Marina Rubinchak for their assistance in obtaining blood samples and data for the study and Dr. Yoel Angel for his insightful comments. 

N, number; Anti-S, anti-Spike antibody; n/a, not applicable